Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Haemorrhagic Complications and Symptomatic Venous Thromboembolism in Interventional Tumour Ablations: The Impact of Peri-interventional Thrombosis Prophylaxis.
Mohnike K, Sauerland H, Seidensticker M, Hass P, Kropf S, Seidensticker R, Friebe B, Fischbach F, Fischbach K, Powerski M, Pech M, Grosser OS, Kettner E, Ricke J. Mohnike K, et al. Among authors: kettner e. Cardiovasc Intervent Radiol. 2016 Dec;39(12):1716-1721. doi: 10.1007/s00270-016-1423-1. Epub 2016 Jul 19. Cardiovasc Intervent Radiol. 2016. PMID: 27435581
Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases.
Seidensticker R, Denecke T, Kraus P, Seidensticker M, Mohnike K, Fahlke J, Kettner E, Hildebrandt B, Dudeck O, Pech M, Amthauer H, Ricke J. Seidensticker R, et al. Among authors: kettner e. Cardiovasc Intervent Radiol. 2012 Oct;35(5):1066-73. doi: 10.1007/s00270-011-0234-7. Epub 2011 Jul 29. Cardiovasc Intervent Radiol. 2012. PMID: 21800231
Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib.
Öcal O, Schinner R, Schütte K, de Toni EN, Loewe C, van Delden O, Vandecaveye V, Gebauer B, Zech CJ, Sengel C, Bargellini I, Gasbarrini A, Sangro B, Pech M, Malfertheiner P, Ricke J, Seidensticker M; SORAMIC study group. Öcal O, et al. Cancer Imaging. 2022 Jan 4;22(1):1. doi: 10.1186/s40644-021-00439-x. Cancer Imaging. 2022. PMID: 34983668 Free PMC article.
Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma.
Ridwelski K, Fahlke J, Kuhn R, Hribaschek A, Kettner E, Greiner C, Florschuetz A, Manger T, Wilhelm G, Klein H, Hahnfeld S, Lippert H, Meyer F. Ridwelski K, et al. Among authors: kettner e. Eur J Surg Oncol. 2006 Apr;32(3):297-302. doi: 10.1016/j.ejso.2005.11.020. Epub 2006 Jan 18. Eur J Surg Oncol. 2006. PMID: 16414235 Clinical Trial.
Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial.
Boeck S, Weigang-Köhler K, Fuchs M, Kettner E, Quietzsch D, Trojan J, Stötzer O, Zeuzem S, Lordick F, Köhne CH, Kröning H, Steinmetz T, Depenbrock H, Heinemann V. Boeck S, et al. Among authors: kettner e. Ann Oncol. 2007 Apr;18(4):745-51. doi: 10.1093/annonc/mdl463. Epub 2007 Jan 17. Ann Oncol. 2007. PMID: 17229775 Free article. Clinical Trial.
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104.
Kruger S, Boeck S, Heinemann V, Laubender RP, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, Fischer von Weikersthal L, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Modest DP, Stintzing S, Haas M. Kruger S, et al. Among authors: kettner e. Acta Oncol. 2015 Jul;54(7):993-1000. doi: 10.3109/0284186X.2015.1034877. Epub 2015 Apr 30. Acta Oncol. 2015. PMID: 25924969 Clinical Trial.
46 results